Investing in fundamentally strong growth shares that act with a reasonable appreciation is a proven strategy to generate great profits over time. In this article I have identified two beaten TSX shares that Canadian investors have to consider buying $ 5,000 now.
Is these healthcare shares a good buy?
Valued on a market capitalization of $ 234 million, In -depth medical (TSX: PRN) is a commercial company for medical device that develops incision-free therapeutic systems and markets for the image-guided ablation of sick tissue in Canada, Germany, the United States and Finland.
In Q1 2025, in-depth medica reported the turnover of $ 2.6 million, an increase of 82% year after year, driven by a strong acceptance of his Tulsa-Prostate Treatment Technology.
Profound achieved an important milestone with positive data from the captain test, the first randomized controlled study in which Tulsa-Pro was compared to robot-like radical prostatectomy. Results showed that Tulsa patients experienced zero blood loss, no overnight stays in the hospital and statistically significantly less pain during the first week after treatment. Patients recovered faster for two weeks than those who underwent traditional surgery.
Profound introduced his Tulsa AI volume eduction module for benign prostatic hyperplasia (BPH), aimed at 60-90 minutes of procedures, regardless of prostate size. The module is launched in a limited release in June, with full implementation planned for Q4 2025.
The new Turnkey Tulsa-Plus program combines MRI equipment with Tulsa technology, making the acceptance feasible for practices that require only two procedures every week to justify the costs. With level 7 Medicare allowance of January 2025, management retains confidence in achieving a revenue growth of 70-75% for the entire year.
Analysts who follow the TSX sharing proceeds to increase from $ 15.2 million in 2024 to $ 250 million in 2029. The company is estimated at 2029 with a free cash flow (FCF) of $ 62.3 million, compared to an outflow of $ 32.5 million this year.
If PRN shares are priced at 15 times ahead FCF, this can win around 300% in the coming four years.
The bull case for this small CAP TSX stock
Valued at $ 230 million per market capitalization, Anaergia (TSX: ANRG) is a TSX share that has won more than 170% in the last 12 months. However, it is also with a 90% decrease of all time, so that you can buy the dip.
Anaergia offers solutions for renewable energy through waste-to-resource conversion technologies, including the production of biogas, waste water treatment and the processing of fixed waste on global markets.
The company delivered a remarkable transformation in 2024 and carried out its “Anaergia 2.0” strategy, which fundamentally repositioned the company of renewable energy company for sustainable growth. The provider of organic waste-to-energy solutions has provided a strategic investment of $ 41 million from Marny Investissement, which strengthens the balance.
Anaergia reported the gross margins of 23% in 2024, an increase of 13.4% in 2023, from which the effectiveness of his capital light strategy was aimed at profitable projects.
While the turnover of the entire year fell by 24.2% to $ 111.6 million as a result of project implementation and strategic divestments, the net losses improved by 71% to $ 55.9 million, which reflects an improved operational discipline and a 35% employee reduction.
Anaergia’s commercial momentum accelerated in Q4 2024 and early 2025, including large contracts, including Pepsico Colombia, Monterey One Water and several Italian biomethane facilities.
It reported $ 103.3 million in income behind with an additional $ 250 million in capital sales opportunities under negotiation. Strategic expansion to fast-growing markets, including Japan, Latin America and Europe, positions it to take advantage of beneficial regulatory tail winds to support renewable natural gas advice.
Analysts who follow the turnover of the TSX sharing forecast to increase from $ 111.6 million in 2024 to $ 1.1 billion in 2029. Anaergia is predicted on 2029 with an FCF of $ 150 million, compared to an outflow of $ 7 million in 2025. Being able to rise over the next four years.
#Top #Canadian #shares #buy